AstraZeneca enters option agreement with Kyowa Hakko Kirin for commercialisation of benralizumab in Japan
AstraZeneca today announced that it has entered an agreement with Kyowa Hakko Kirin Co. Ltd. (Kyowa Hakko Kirin) for an exclusive option to commercialise benralizumab for asthma and chronic obstructive pulmonary disease (COPD) in Japan